Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy

Luo,Pei; Yang,Qing; Cong,Le‑Le; Wang,Xiao‑Feng; Li,Yu‑Sheng; Zhong,Xiao‑Ming; Xie,Ru‑Ting; Jia,Cheng‑You; Yang,Hui‑Qiong; Li,Wen‑Ping; Cong,Xian‑Ling; Xia,Qing; Fu,Da; Zeng,Qing‑Hua; Ma,Yu‑Shui

doi:10.3892/mmr.2017.6595

Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy

Authors:
- Pei Luo
- Qing Yang
- Le‑Le Cong
- Xiao‑Feng Wang
- Yu‑Sheng Li
- Xiao‑Ming Zhong
- Ru‑Ting Xie
- Cheng‑You Jia
- Hui‑Qiong Yang
- Wen‑Ping Li
- Xian‑Ling Cong
- Qing Xia
- Da Fu
- Qing‑Hua Zeng
- Yu‑Shui Ma
View Affiliations

Affiliations: College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, P.R. China, Department of Neurology, China Japan Union Hospital, Jilin University, Changchun, Jilin 130031, P.R. China, Department of Orthopedics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Orthopedics, Xiangya Hospital, Central‑South University, Changsha, Hunan 410008, P.R. China, Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi 330029, P.R. China, Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China, Tissue Bank, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China, Department of Respiratory, The First Affiliated Hospital of Nanchang University, Nanchang 330006, P.R. China
Published online on: May 17, 2017 https://doi.org/10.3892/mmr.2017.6595
Pages: 238-246
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have suggested that dysregulation of microRNA (miR) -124a is associated with various types of human cancer. However, there are few studies reporting the level of miR‑124a expression in non‑small cell lung cancer (NSCLC). The present study investigated the association between miR‑124a and NSCLC by analyzing the differential expression of miR‑124a in NSCLC using the GEO database, as well as subsequently performing reverse transcription‑quantitative polymerase chain reaction analysis on 160 NSCLC biopsies, 32 of which were paired with adjacent normal tissues. The results indicated that mir‑124a expression levels were decreased in NSCLC tumor biopsies compared with adjacent normal tissues. The overall survival (OS) in patients with a high expression of miR‑124a was prolonged relative to patients with low expression of miR‑124a. The expression levels of miR‑124a were associated with clinical characteristics, including lymph‑node metastasis, tumor differentiation, tumor node metastasis (TNM) stage and diameter. Frequently, lymph‑node metastasis, TNM stage, diameter and lack of chemotherapy have been associated with a worse prognosis in patients. In addition, the present study identified that high expression of miR‑124awith chemotherapy may increase OS. In conclusion, the current study demonstrated that miR‑124a was downregulated in NSCLC, and miR‑124a was a potential prognostic tumor biomarker response to chemotherapy.

View Figures

View References

1	Hamamoto J, Soejima K, Yoda S, Naoki K, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Yasuda H, et al: Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep. 8:456–462. 2013.PubMed/NCBI
2	Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, et al: MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 19:5423–5433. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, et al: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
4	Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
5	Mitra R, Edmonds MD, Sun J, Zhao M, Yu H, Eischen CM and Zhao Z: Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA. 20:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
6	Xie J, Yu F, Li D, Zhu X, Zhang X and Lv Z: MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol. 37:1197–1204. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhou YL, Xu YJ and Qiao CW: MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 8:6312–6322. 2015.PubMed/NCBI
8	Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, San José-Eneriz E, Abizanda G, Rodríguez-Otero P, Fortes P, et al: Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69:4443–4453. 2009. View Article : Google Scholar : PubMed/NCBI
9	Pierson J, Hostager B, Fan R and Vibhakar R: Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 90:1–7. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhao G, Liu L, Zhao T, Jin S, Jiang S, Cao S, Han J, Xin Y, Dong Q, Liu X and Cui J: Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol. 36:3693–3701. 2015. View Article : Google Scholar : PubMed/NCBI
11	Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, et al: MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 129:2621–2631. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu F, Wang X, Li J, Gu K, Lv L, Zhang S, Che D, Cao J, Jin S and Yu Y: miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer. Cell Prolif. 48:582–592. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yu SH, Zhang CL, Dong FS and Zhang YM: miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. 116:268–276. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ruike Y, Ichimura A, Tsuchiya S, Shimizu K, Kunimoto R, Okuno Y and Tsujimoto G: Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines. J Hum Genet. 53:515–523. 2008. View Article : Google Scholar : PubMed/NCBI
15	Keller A, Leidinger P, Vogel B, Backes C, ElSharawy A, Galata V, Mueller SC, Marquart S, Schrauder MG, Strick R, et al: miRNAs can be generally associated with human pathologies as exemplified for miR-144. BMC Med. 12:2242014. View Article : Google Scholar : PubMed/NCBI
16	Robles AI, Arai E, Mathé EA, Okayama H, Schetter AJ, Brown D, Petersen D, Bowman ED, Noro R, Welsh JA, et al: An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol. 10:1037–1048. 2015. View Article : Google Scholar : PubMed/NCBI
17	Keller A, Leidinger P, Borries A, Wendschlag A, Wucherpfennig F, Scheffler M, Huwer H, Lenhof HP and Meese E: miRNAs in lung cancer-studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer. 9:3532009. View Article : Google Scholar : PubMed/NCBI
18	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7^th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli G, et al: miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 31:634–642. 2012.PubMed/NCBI
22	Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18:74–82. 2011.PubMed/NCBI
23	Hou LK, Ma YS, Han Y, Lu GX, Luo P, Chang ZY, Xie RT, Yang HQ, Chai L, Cai MX, et al: Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy. PLoS One. 12:e01704312017. View Article : Google Scholar : PubMed/NCBI
24	Faversani A, Amatori S, Augello C, Colombo F, Porretti L, Fanelli M, Ferrero S, Palleschi A, Pelicci PG, Belloni E, et al: miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget. 8:7231–7247. 2017.PubMed/NCBI
25	Zhou Q, Long L, Zhou T, Tian J and Zhou B: Demethylation of MicroRNA-124a genes attenuated proliferation of rheumatoid arthritis derived fibroblast-like synoviocytes and synthesis of tumor necrosis factor-α. PLoS One. 11:e01642072016. View Article : Google Scholar : PubMed/NCBI
26	Ben Gacem R, Ben Abdelkrim O, Ziadi S, Ben Dhiab M and Trimeche M: Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease. Tumour Biol. 35:4047–4056. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR and Zhao Q: MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 34:713–722. 2013. View Article : Google Scholar : PubMed/NCBI
28	Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C and McDonald KL: The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol. 35:1459–1465. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lu SH, Jiang XJ, Xiao GL, Liu DY and Yuan XR: miR-124a restoration inhibits glioma cell proliferation and invasion by suppressing IQGAP1 and β-catenin. Oncol Rep. 32:2104–2110. 2014.PubMed/NCBI
30	Deng G, Kakar S and Kim YS: MicroRNA-124a and microRNA-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett. 2:175–180. 2011.PubMed/NCBI
31	Ueda Y, Ando T, Nanjo S, Ushijima T and Sugiyama T: DNA methylation of microRNA-124a is a potential risk marker of colitis-associated cancer in patients with ulcerative colitis. Dig Dis Sci. 59:2444–2451. 2014. View Article : Google Scholar : PubMed/NCBI
32	Chen X, He D, Dong XD, Dong F, Wang J, Wang L, Tang J, Hu DN, Yan D and Tu L: MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci. 54:2248–2256. 2013. View Article : Google Scholar : PubMed/NCBI
33	He T, Feng G, Chen H, Wang L and Wang Y: Identification of host encoded microRNAs interacting with novel swine-origin influenza A (H1N1) virus and swine influenza virus. Bioinformation. 4:112–118. 2009. View Article : Google Scholar : PubMed/NCBI
34	Kim YH, Lee WK, Lee EB, Son JW, Kim DS and Park JY: Combined effect of metastasis-related MicroRNA, miR-34 and miR-124 family, methylation on prognosis of non-small-cell lung cancer. Clin Lung Cancer. 18:e13–e20. 2017. View Article : Google Scholar : PubMed/NCBI
35	Li X, Yu Z, Li Y, Liu S, Gao C, Hou X, Yao R and Cui L: The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients. Int J Oncol. 46:798–808. 2015.PubMed/NCBI
36	Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13:247–255. 2012. View Article : Google Scholar : PubMed/NCBI
37	Lee SH, Jung SH, Kim TM, Rhee JK, Park HC, Kim MS, Kim SS, An CH, Lee SH and Chung YJ: Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget. 8:6579–6588. 2017.PubMed/NCBI
38	Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR and Goel A: MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 113:83–90. 2015. View Article : Google Scholar : PubMed/NCBI
39	Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A and Adamo V: Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 229:97–99. 2014.PubMed/NCBI
40	Wang F, Lou JF, Cao Y, Shi XH, Wang P, Xu J, Xie EF, Xu T, Sun RH, Rao JY, et al: miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med. 47:e1622015. View Article : Google Scholar : PubMed/NCBI
41	Tanaka K, Miyata H, Yamasaki M, Sugimura K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and Doki Y: Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol. 20:(Suppl 3). S607–S615. 2013. View Article : Google Scholar : PubMed/NCBI
42	Miyamae M, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A, et al: Plasma microRNA profiles: Identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br J Cancer. 113:1467–1476. 2015. View Article : Google Scholar : PubMed/NCBI
43	Frères P, Josse C, Bovy N, Boukerroucha M, Struman I, Bours V and Jerusalem G: Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. J Cell Physiol. 230:473–481. 2015. View Article : Google Scholar : PubMed/NCBI